Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,773 signal articles · 68 in last 24h · 148,348 total before filter · latest 1h ago
68last 24h
974last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
AllMacro369Earnings115M&A98Regulatory8Product11Analyst10
✕ clear all filtersticker: NVOsentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
Simply Wall St.135d agobullish
Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...

Novo Nordisk beats estimates, raises guidance on Wegovy pill surge
Proactive136d agobullish
Novo Nordisk beats estimates, raises guidance on Wegovy pill surge

Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had...